Literature DB >> 11244026

Effects of angiotensin-converting enzyme inhibitor and angiotensin type 1 receptor antagonist in deoxycorticosterone acetate-salt hypertensive mice lacking Ren-2 gene.

H Peng1, O A Carretero, M E Alfie, J A Masura, N E Rhaleb.   

Abstract

We previously reported that inhibition of angiotensin-converting enzyme (ACE) prevented the hypertension and left ventricular hypertrophy induced by deoxycorticosterone acetate-salt (DOCA-salt) in 129/SvEvTac mice, which have 2 renin genes (Ren-1 and Ren-2). In the present study, we induced hypertension by uninephrectomy and DOCA-salt in mice having only the Ren-1 gene (C57BL/6J) and investigated the effect of an ACE inhibitor (ramipril, 4 mg. kg(-)(1). d(-)(1)) and an angiotensin type 1 (AT(1)) receptor antagonist (L-158809, 4 mg. kg(-)(1). d(-)(1)) on the development of hypertension, cardiac hypertrophy, and renal injury. After 4 weeks of treatment, systolic blood pressure in DOCA-salt mice was significantly increased (128+/-2 mm Hg) compared with controls (109+/-2 mm Hg) (P:<0.001), while plasma renin concentration was decreased by 97% (P:<0.001). DOCA-salt also induced left ventricular and renal hypertrophy and renal damage as manifested by proteinuria. Collagen content in the left ventricle and kidney was significantly higher in DOCA-salt mice (P:<0.001). Urinary albumin (P:<0.05) and proliferating cell nucleic antigen-positive cells in the tubules and interstitium of the renal cortex (P:<0.001) were significantly increased in the DOCA-salt group. Neither the ACE inhibitor nor the AT(1) antagonist had any antihypertensive effect; however, they partially prevented cardiac hypertrophy and completely inhibited left ventricular collagen deposition. In the kidney, both the ACE inhibitor and AT(1) antagonist partially reduced the increase in collagen but had no effect on hypertrophy. They also significantly prevented the effect of DOCA-salt on urinary albumin and proliferating cell nucleic antigen expression in the kidney. Despite the lack of an antihypertensive effect, both ACE inhibitor and AT(1) antagonist prevented cardiac remodeling and renal damage. Our results indicate that ACE inhibitors and AT(1) antagonists exert beneficial effects on the heart and kidney in DOCA-salt hypertensive mice independently of their effects on blood pressure.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11244026     DOI: 10.1161/01.hyp.37.3.974

Source DB:  PubMed          Journal:  Hypertension        ISSN: 0194-911X            Impact factor:   10.190


  15 in total

1.  Deletion of transient receptor potential vanilloid type 1 receptors exaggerates renal damage in deoxycorticosterone acetate-salt hypertension.

Authors:  Youping Wang; Dagmar Babánková; Jie Huang; Greg M Swain; Donna H Wang
Journal:  Hypertension       Date:  2008-07-07       Impact factor: 10.190

2.  Renal protective effects of N-acetyl-Ser-Asp-Lys-Pro in deoxycorticosterone acetate-salt hypertensive mice.

Authors:  Nour-Eddine Rhaleb; Saraswati Pokharel; Umesh Sharma; Oscar A Carretero
Journal:  J Hypertens       Date:  2011-02       Impact factor: 4.844

3.  Local angiotensin II aggravates cardiac remodeling in hypertension.

Authors:  Jiang Xu; Oscar A Carretero; Tang-Dong Liao; Hongmei Peng; Edward G Shesely; Junxiao Xu; Thomas S Liu; James J Yang; Timothy L Reudelhuber; Xiao-Ping Yang
Journal:  Am J Physiol Heart Circ Physiol       Date:  2010-09-10       Impact factor: 4.733

4.  Reversible cardiac fibrosis and heart failure induced by conditional expression of an antisense mRNA of the mineralocorticoid receptor in cardiomyocytes.

Authors:  Ahmed T Beggah; Brigitte Escoubet; Stefania Puttini; Stephane Cailmail; Vanessa Delage; Antoine Ouvrard-Pascaud; Brigitte Bocchi; Michel Peuchmaur; Claude Delcayre; Nicolette Farman; Frederic Jaisser
Journal:  Proc Natl Acad Sci U S A       Date:  2002-05-07       Impact factor: 11.205

5.  Arrhythmogenic Remodeling in Murine Models of Deoxycorticosterone Acetate-Salt-Induced and 5/6-Subtotal Nephrectomy-Salt-Induced Cardiorenal Disease.

Authors:  Magda S C Fontes; Diana A Papazova; Arianne van Koppen; Sanne de Jong; Sanne M Korte; Lennart G Bongartz; Tri Q Nguyen; Marti F A Bierhuizen; Teun P de Boer; Toon A B van Veen; Marianne C Verhaar; Jaap A Joles; Harold V M van Rijen
Journal:  Cardiorenal Med       Date:  2015-06-05       Impact factor: 2.041

6.  Murine and rat cavernosal responses to endothelin-1 and urotensin-II Vasoactive Peptide Symposium.

Authors:  Fernando S Carneiro; Zidonia N Carneiro; Fernanda R C Giachini; Victor V Lima; Edson Nogueira; William E Rainey; Rita C Tostes; R Clinton Webb
Journal:  J Am Soc Hypertens       Date:  2008-11

7.  Role of N-acetyl-seryl-aspartyl-lysyl-proline in the antifibrotic and anti-inflammatory effects of the angiotensin-converting enzyme inhibitor captopril in hypertension.

Authors:  Hongmei Peng; Oscar A Carretero; Tang-Dong Liao; Edward L Peterson; Nour-Eddine Rhaleb
Journal:  Hypertension       Date:  2007-02-05       Impact factor: 10.190

8.  Effects of AT1 receptor blockade on renal injury and mitogen-activated protein activity in Dahl salt-sensitive rats.

Authors:  Akira Nishiyama; Masanori Yoshizumi; Matlubur Rahman; Hiroyuki Kobori; Dale M Seth; Akira Miyatake; Guo-Xing Zhang; Li Yao; Hirofumi Hitomi; Takatomi Shokoji; Hideyasu Kiyomoto; Shoji Kimura; Toshiaki Tamaki; Masakazu Kohno; Youichi Abe
Journal:  Kidney Int       Date:  2004-03       Impact factor: 10.612

9.  DOCA-salt treatment enhances responses to endothelin-1 in murine corpus cavernosum.

Authors:  Fernando S Carneiro; Fernanda R C Giachini; Victor V Lima; Zidonia N Carneiro; Kênia P Nunes; Adviye Ergul; Romulo Leite; Rita C Tostes; R Clinton Webb
Journal:  Can J Physiol Pharmacol       Date:  2008-06       Impact factor: 2.273

10.  Transient receptor potential vanilloid gene deletion exacerbates inflammation and atypical cardiac remodeling after myocardial infarction.

Authors:  Wei Huang; Jack Rubinstein; Alejandro R Prieto; Loc Vinh Thang; Donna H Wang
Journal:  Hypertension       Date:  2008-12-29       Impact factor: 10.190

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.